Compare Organon & Co. Common Stock (OGN) vs ON Semiconductor (ON) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Organon & Co. Common Stock vs ON Semiconductor — how do they compare? Organon & Co. Common Stock trades at $13.58 (market cap $3.62B), while ON Semiconductor trades at $72.51 (market cap $29.86B). The key difference: ON Semiconductor is far larger — about 8.2× Organon & Co. Common Stock's market cap, and Organon & Co. Common Stock pays a 0.58% dividend while ON Semiconductor pays none. Which is the better fit depends on your goals — on Pluang, investors hold Organon & Co. Common Stock for 0 Days and ON Semiconductor for 7 Days on average.
| OGN | ON | |
|---|---|---|
Market Cap | $3.62B | $29.86B |
Volume | 2,892,999 | 7,140,901 |
Sector | Health | Technology |
52-Week High | $13.81 | $133.93 |
52-Week Low | $5.70 | $44.90 |
Typical Hold Time | 0 Days | 7 Days |
Enterprise Value | $11.04B | $30.48B |
Dividend Yield | 0.58% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
ON Semiconductor (ON) trades at $76.69, up 0.91% on the day, with technical indicators showing bearish momentum despite recent earnings beats. The company reported strong Q2 2026 results with 9% revenue growth and significant EPS expansion, while analyst consensus remains positive with a $100 price target. Recent news highlights the revised Synaptics acquisition and AI infrastructure opportunities.
The stock presents a turnaround story with improving profitability and AI growth potential, though technical weakness and competitive pressures warrant caution. Upside catalysts include margin expansion and data center demand, while risks include integration challenges from the Synaptics deal and semiconductor cycle volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →About ON Semiconductor
Onsemi develops power and sensing semiconductors for automotive, industrial, and energy applications. Its products support functions such as electric vehicle systems, energy conversion, automation, and intelligent sensing.
Read more on ON →
